On October 8, 2018 Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, reported that data from the study of DKN-01 in combination with KEYTRUDA (pembrolizumab) in patients with advanced gastroesophageal cancer will be presented in a poster presentation at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) 2018 Annual Congress, taking place October 19-23, 2018 in Munich, Germany(Press release, Leap Therapeutics, OCT 8, 2018, View Source;p=RssLanding&cat=news&id=2370704 [SID1234529886]). The abstract was published online in advance of the poster presentation that will include additional patient data as the study has progressed since abstract submission.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
About the DKN-01 P102 clinical trial:
The P102 esophagogastric cancer study is a multipart study evaluating DKN-01 as a monotherapy and in combination with paclitaxel or pembrolizumab in patients with advanced relapsed or refractory esophagogastric cancer. The arm evaluating DKN-01 with pembrolizumab includes both dose escalation and dose confirmation cohorts and is designed to evaluate the safety, pharmacokinetics and efficacy of the combination. Patients will receive DKN-01 (150 mg or 300 mg on Days 1 & 15) plus pembrolizumab (200 mg on Day 1) of each 21-day cycle. The dose expansion cohort (n=55) includes patients that are naïve (n=40) or refractory (n=15) to PD-1/PD-L1 antagonists.
Leap Poster Presentation Details
Presentation Number: 660P
Title: Safety and Efficacy of a DKK1 Inhibitor (DKN-01) in Combination with Pembrolizumab (P) in Patients (Pts) with Advanced Gastroesophageal (GE) Malignancies
Session Title: Gastrointestinal tumours – colorectal & non-colorectal
Date: October 21, 2018
Time: 12:45pm – 1:45pm CEST
Location: Hall A3 – Poster Area Networking Hub, ICM München